







an Open Access Journal by MDPI

# State-of-the-Art Drug Delivery in the UK

Guest Editors:

Prof. Dr. Ali Nokhodchi

Dr. Kofi Asare-Addo

Prof. Dr. Raid Alany

Deadline for manuscript submissions:

closed (30 November 2023)

# **Message from the Guest Editors**

In this Special Issue, we solicit the submission of original articles from researchers based in the UK or review articles where the main focus of the article is research carried out in the UK in the field of drug delivery (based on the keywords below).

- nanomedicines
- macromolecule delivery
- 3D printing
- microneedle
- transdermal delivery
- pulmonary delivery
- nasal delivery
- ocular delivery
- brain delivery
- oral delivery
- nanofibers
- novel drug-delivery systems







IMPACT FACTOR 4.7





an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

# **Message from the Editor-in-Chief**

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

#### **Contact Us**